FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

		/														
Name and Address of Reporting Person* LYONS GARY A				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/23/2019							Officer (give	e title below)		er (specify belo	ow)	
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing/Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Table I - Non-Derivative Securities Acqu					Acquired	tired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yes			2A. Deemed Execution Da any (Month/Day/		if Coo	3. Transaction Code (Instr. 8)		4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		f (D) Own Trai	5. Amount of Securities Be Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							ode	V A		.) or D)	Price	(I)			(I) (Instr. 4)	,
						l direct	i	in this f	s who res	ot re	quired to		unless the	tion contain form	ied SEC	1474 (9-02)
			Table II -			ities A	i cquire	in this f displays ed, Dispo	s who res orm are n s a curren sed of, or l	ot re itly v Benef	equired to alid OMB	respond control r	unless the		ned SEC	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	ts, calls, 5. Notion of I Second According to 1	umber verivati urities uired (cquirects, opt 6. I Exp (Mo	in this f displays ed, Dispo tions, co	s who resorm are not a current sed of, or leavertible servisable and pate	not rently v	equired to alid OMB	respond control r rned d Amount	unless the number.	9. Number of Derivative Securities Beneficially Owned	of 10. Owners Form of Derivati Security	11. Naturipi of Indire Beneficis ve Ownersh
Derivative Security	Conversion or Exercise Price of	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion of I Second of I Second of I	umber verivati urities uired (vispose D)	cquirects, opt 6. I Exp (Mo	in this f displays ed, Dispo tions, con Date Exe piration I	s who resorm are not a current sed of, or leavertible servisable and pate	not rently v	quired to alid OMB ficially Ow ties) 7. Title and of Underly Securities	respond control r rned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Owners Form of Derivati Security Direct (or Indir	11. Natur of Indire Beneficia ve Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls, 5. N of I Sec or I of ((Ins	umber variations uired (bispose D) tr. 3, 4, 5)	cquirects, opt 6. I Exp (Mo	in this f displays ed, Dispo tions, cor Date Exe piration I onth/Day	s who resorm are not a current sed of, or I nvertible so reisable and Date y/Year)	not rently value of the court o	quired to alid OMB ficially Ow ties) 7. Title and of Underly Securities	respond control r rned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following	of 10. Owners Form of Derivati Security Direct (or Indir	11. Natur of Indire Beneficis Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
LYONS GARY A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

/s/Dolly Vance (Attorney-in-Fact)	05/24/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares shall vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.